Incorporating voluntary patient preference information over the total product life cycle (Catapult’s regulatory round-up – September 2024)
The FDA has issued a draft guidance to propose revisions to the 2016 guidance to reflect the current scope of FDA’s benefit-risk paradigm, which may under appropriate circumstances, include patient preference information (PPI), and to provide additional...